Drug intelligence / Profile preview

HDM3010

Development stage: Unknown
Lead developer: Hangzhou Zhongmei Huadong Pharmaceutical
Administration: Topical

Overview

HDM3010 is an investigational drug developed by Hangzhou Zhongmei Huadong Pharmaceutical and Huadong Pharmaceutical (Xi'an) Bohua Pharmaceutical. It is being studied as a topical therapy for dermatological conditions, specifically prurigo nodularis and vitiligo. The precise mechanism of action for HDM3010 has not been disclosed publicly, and it is described as having an unknown or novel mechanism. Clinical trials are ongoing in China, including a multicenter, randomized, double-blind, placebo-controlled phase III study in patients with vitiligo and a phase I/II study evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in adults with prurigo nodularis[2][4]. The drug has not received regulatory approval in any country.

Brand names: HDM3010HDM-3010HDM 3010
Other names: HDM3010HDM-3010HDM 3010

Beyond the preview

Go deeper on HDM3010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HDM3010.

Explore the full profile